BidaskClub upgraded shares of Xencor (NASDAQ:XNCR) from a hold rating to a buy rating in a research report released on Tuesday.
A number of other analysts also recently issued reports on XNCR. Zacks Investment Research downgraded shares of Xencor from a hold rating to a sell rating in a report on Saturday, November 11th. Piper Jaffray Companies reiterated a buy rating and issued a $35.00 price objective on shares of Xencor in a report on Sunday, November 12th. Finally, Cantor Fitzgerald initiated coverage on shares of Xencor in a report on Wednesday, November 29th. They issued an overweight rating and a $33.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. Xencor currently has a consensus rating of Hold and an average price target of $30.80.
Shares of Xencor (NASDAQ XNCR) opened at $29.41 on Tuesday. Xencor has a fifty-two week low of $18.55 and a fifty-two week high of $29.91. The stock has a market cap of $1,380.00, a P/E ratio of -29.12 and a beta of 1.97.
Large investors have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can grew its stake in shares of Xencor by 158.9% in the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 4,005 shares in the last quarter. Principal Financial Group Inc. bought a new position in shares of Xencor in the third quarter valued at $201,000. UBS Asset Management Americas Inc. bought a new position in shares of Xencor in the fourth quarter valued at $205,000. Landscape Capital Management L.L.C. bought a new position in shares of Xencor in the fourth quarter valued at $220,000. Finally, Two Sigma Advisers LP bought a new position in shares of Xencor in the fourth quarter valued at $278,000. 77.11% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Xencor (XNCR) Rating Increased to Buy at BidaskClub” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3227317/xencor-xncr-rating-increased-to-buy-at-bidaskclub.html.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.